Automate Your Wheel Strategy on ANAB
With Tiblio's Option Bot, you can configure your own wheel strategy including ANAB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ANAB
- Rev/Share 3.6507
- Book/Share 1.1102
- PB 20.3206
- Debt/Equity 0.4578
- CurrentRatio 8.2456
- ROIC -0.264
- MktCap 662824080.0
- FreeCF/Share -3.3354
- PFCF -6.4849
- PE -4.9161
- Debt/Assets 0.0369
- DivYield 0
- ROE -2.8247
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ANAB | Wolfe Research | -- | Outperform | -- | $25 | Feb. 4, 2025 |
| Downgrade | ANAB | H.C. Wainwright | Buy | Neutral | $52 | $19 | Dec. 11, 2024 |
News
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Negative
AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $1.61. This compares to loss of $1.59 per share a year ago.
Read More
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs. placebo Achieved statistical significance on key secondary endpoints at Week 12 on ACR20, ACR50 and CDAI LDA Demonstrated highest ever reported responses on key secondary endpoints at Week 14 on ACR20, ACR50, ACR70 and CDAI LDA 69% of rosnilimab-treated patients achieved CDAI LDA at Week 14 and appear to show sustained CDAI LDA and ACR50 responses and potentially deepening ACR70 responses out to Week 28 Robust pharmacological activity observed in reduction of PD-1high T cells, increase in total Tregs …
Read More
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast to review top-line data from the global Phase 2b RENOIR clinical trial of investigational rosnilimab, a depleter and agonist of PD-1+ T cells, for moderate-to-severe rheumatoid arthritis on Wednesday, Feb. 12, 2025, at 8:30am ET / 5:30am PT.
Read More
About AnaptysBio, Inc. (ANAB)
- IPO Date 2017-01-26
- Website https://www.anaptysbio.com
- Industry Biotechnology
- CEO Mr. Daniel R. Faga
- Employees 136